Division of Cardiology, Sir Mortimer B. Davis-Jewish General Hospital and Lady Davis Institute for Medical Research Montreal, QC, Canada.
Front Pharmacol. 2013 Mar 12;4:19. doi: 10.3389/fphar.2013.00019. eCollection 2013.
In the context of modern cancer chemotherapeutics, cancer survivors are living longer and being exposed to potential comorbidities related to non-cancer side effects of such treatments. With close monitoring of cancer patients receiving potentially cardiotoxic medical therapies, oncologists, and cardiologists alike are identifying patients in both clinical and subclinical phases of cardiovascular disease related to such chemotherapies. Specifically, cardiotoxicity at the level of the myocardium and potential for the development of heart failure are becoming a growing concern with increasing survival of cancer patients. Traditional chemotherapeutic agents used commonly in the treatment of breast cancer and hematologic malignancies, such as anthracyclines and HER-2 antagonists, are well known to be associated with cardiovascular sequelae. Patients often present without symptoms and an abnormal cardiac imaging study performed as part of routine evaluation of patients receiving cardiotoxic therapies. Additionally, patients can present with signs and symptoms of cardiovascular disease months to years after receiving the chemotherapies. As the understanding of the physiology underlying the various cancers has grown, therapies have been developed that target specific molecules that represent key aspects of physiologic pathways responsible for cancer growth. Inhibition of these pathways, such as those involving tyrosine kinases, has lead to the potential for cardiotoxicity as well. In view of the potential cardiotoxicity of specific chemotherapies, there is a growing interest in identifying patients who are at risk of cardiotoxicity prior to becoming symptomatic or developing cardiotoxicity that may limit the use of potentially life-saving chemotherapy agents. Serological markers and novel cardiac imaging techniques have become the source of many investigations with the goal of screening patients for pre-clinical cardiotoxicity. Additionally, studies have been performed.
在现代癌症化疗中,癌症幸存者的寿命更长,并且由于这些治疗的非癌症副作用而面临潜在的合并症。通过密切监测接受潜在心脏毒性药物治疗的癌症患者,肿瘤学家和心脏病专家都在识别处于心血管疾病临床和亚临床阶段的患者,这些疾病与这些化疗有关。具体而言,心肌毒性和因化疗而导致心力衰竭的可能性,是癌症患者生存时间延长后越来越令人担忧的问题。在治疗乳腺癌和血液恶性肿瘤等疾病中常用的传统化疗药物,如蒽环类药物和 HER-2 拮抗剂,众所周知与心血管后遗症有关。患者通常没有症状,在接受心脏毒性治疗的患者常规评估中进行的异常心脏成像研究。此外,患者在接受化疗后数月至数年可能出现心血管疾病的症状和体征。随着对各种癌症相关生理学的理解不断加深,已经开发出针对特定分子的疗法,这些分子代表负责癌症生长的生理途径的关键方面。这些途径的抑制,如涉及酪氨酸激酶的途径,也可能导致心脏毒性。鉴于某些化疗药物具有潜在的心脏毒性,人们越来越感兴趣的是在出现症状或出现可能限制潜在救命化疗药物使用的心脏毒性之前,识别出有心脏毒性风险的患者。血清标志物和新型心脏成像技术已成为许多研究的来源,旨在为临床前心脏毒性筛查患者。此外,已经进行了研究。